stockrowBioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
- Revenue
- −3.29%
- EPS
- +31.9%
- Free cash flow
- −1,827.7%
- Total debt
- −40.2%
Quarter to June 2026, against a year earlier
Follow BLRX
Alert me
BioLineRx Ltd. (BLRX) EV/Sales
As of 5 November 2026, BioLineRx Ltd. (BLRX) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from −2.3× (March 2026) to 5.9× (July 2026); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.5× | — |
| FY2024 | 0.4× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.4× | 1,002.40% |
| Mar 2026 | 0.5× | — |
| Dec 2025 | −0.5× | — |
| Sep 2025 | 0.1× | 60.79% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CALC CalciMedica Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| BLRX BioLineRx Ltd. | 1.1× |
| ICU SeaStar Medical Holding Corporation compare | 2.0× |
| TPST Tempest Therapeutics, Inc. compare | 22.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)